Anatomy & Physiology Study Guide
26

The Lymphatic and Immune Systems

Slide deck, chapter 2627 slidesChapter outline and sourcesPractice questions

  1. 26.1

    From interstitial space to the venous angle

    • Initial lymphatics are blind-ended tubes of one-cell-thick endothelium whose overlapping cells act as one-way flaps; collagen filaments anchor them to the tissue.
    • Rising interstitial pressure makes the filaments tug the flaps open, so fluid, protein and cells enter but cannot leak back out.
    • Flow then runs through valved collecting vessels, nodes, lymph trunks and finally ducts that empty into the junction of the internal jugular and subclavian veins.
    • Intestinal lacteals carry dietary fat as milky chyle into the same system; the CNS, bone marrow, bone, teeth and cornea have no lymphatics.

    Outcome

    1. 1Trace lymph from an interstitial initial lymphatic through collecting vessels, nodes and trunks to the venous angle.
  2. 26.1

    Two ducts, unequal territories

    • The thoracic duct begins at the cisterna chyli, anterior to the second lumbar vertebra, and is the main duct returning lymph to blood.
    • From the cisterna chyli it passes through the aortic hiatus, ascends in the posterior mediastinum right of the oesophagus and inclines left at about the fifth thoracic vertebra.
    • It receives lumbar and intestinal trunks, then in the neck the left jugular, subclavian and bronchomediastinal trunks; it empties at the left venous angle.
    • So it drains everything below the ribs plus the left head, neck, chest and left upper limb.
    • The right lymphatic duct drains only the upper right body (right jugular, subclavian and bronchomediastinal trunks) into the right venous angle.

    Outcome

    1. 2Distinguish the territories drained by the thoracic duct from those drained by the right lymphatic duct.
  3. 26.1

    What moves lymph without a heart

    • Capillary filtration leaves about 3 L/day that venous reabsorption cannot recover; OpenStax counts 20 L filtered, 17 L reabsorbed.
    • Plasma protein cannot diffuse back into capillaries against its gradient, so lymphatics are the only route that returns it.
    • Driving forces are interstitial pressure, rhythmic contraction of collecting-vessel smooth muscle, skeletal-muscle squeeze and the respiratory pump.
    • Valves, set close together and giving a beaded look, make every compression push lymph toward the heart; blockage causes protein-rich lymphedema.

    Outcome

    1. 3Explain how interstitial pressure, smooth-muscle pumping, skeletal-muscle action and valves generate and direct lymph flow.
  4. 26.1

    Lymph node architecture and the route through it

    • Afferent vessels pierce the capsule and empty into the subcapsular sinus; lymph then percolates past cortex and paracortex to the medullary sinuses and out one efferent vessel.
    • Cortex holds B-cell follicles; a germinal centre marks an activated follicle. Paracortex is the T-cell and dendritic-cell zone.
    • Medulla has cords of B cells and plasma cells between sinuses lined with macrophages.
    • Blood-borne lymphocytes enter through high endothelial venules (tall, plump endothelium) in the paracortex rather than through lymph.
    • Related MALT: palatine, pharyngeal and lingual tonsils (Waldeyer ring, with crypts), Peyer patches and the appendix; tonsils lack afferent lymphatics.

    Outcome

    1. 4Describe the cortex, paracortex and medulla of a lymph node and the route of lymph and cells through it.
  5. 26.1

    Spleen: white pulp versus red pulp

    • White pulp surrounds a central arteriole: a cuff of T cells (the periarteriolar lymphoid sheath) with B-cell follicles set along it, and a marginal zone at the edge.
    • Red pulp is splenic cords (of Billroth) and venous sinusoids full of red cells and macrophages; it filters blood and clears aged red cells.
    • On a section, look for a round pale island around a small artery (white pulp) in a sea of red-stained cords (red pulp).
    • Blood-borne antigen meets lymphocytes here, since the spleen has no afferent lymphatics.
    • Asplenia predisposes to infection by encapsulated organisms such as Streptococcus pneumoniae, Haemophilus and Neisseria.

    Outcome

    1. 5Identify the red pulp, white pulp and periarteriolar lymphoid sheath of the spleen on a section.
  6. 26.1

    Thymus: cortex, medulla, Hassall corpuscles

    • A bilobed organ behind the sternum and in front of the great vessels; capsular trabeculae divide it into lobules that involute after puberty.
    • Cortex is darkly stained and packed with thymocytes; medulla is paler, with fewer thymocytes and more epithelial cells.
    • Hassall (thymic) corpuscles are concentric whorls of flattened keratinising epithelial cells in the medulla; their role is uncertain.
    • Thymic epithelium selects T cells: cortical epithelium tests thymocytes for MHC recognition, and medullary antigen-presenting cells remove strongly self-reactive ones.

    Outcome

    1. 6Identify the cortex, medulla and Hassall corpuscles of the thymus and state the role of the thymic epithelium.
  7. 26.1

    Sentinel nodes and staging

    • A sentinel node is the first node to receive lymph from a tumour; if it is clear, downstream nodes are usually clear, so full dissection can be spared.
    • Breast lymph drains chiefly to axillary nodes (roughly 75-85%), with the inner quadrants also reaching parasternal (internal thoracic) nodes (roughly 15-25%); the upper limb drains to axillary nodes.
    • Head and neck drain to submental, submandibular and deep cervical nodes (jugulo-omohyoid node for the tongue); an enlarged left supraclavicular (Virchow) node signals abdominal cancer.
    • Nodal involvement raises cancer stage, so node status shapes prognosis and adjuvant treatment.

    Outcome

    1. 7Identify the sentinel nodes of the breast, upper limb and head and neck and relate them to cancer staging.
  8. 26.2

    First-line barriers

    • Physical barriers are intact keratinised skin, mucous membranes and ciliary mucus clearance, which block entry or sweep microbes away.
    • Chemical barriers include acidic secretions, sebum, lysozyme in tears and saliva, and antimicrobial peptides called defensins.
    • Microbiological barrier: commensal flora compete with pathogens for nutrients and sites.
    • These act at once and non-specifically, before any cell has to recognise a particular pathogen.

    Outcome

    1. 8Classify the physical, chemical and microbiological barriers that make up the first line of defence.
  9. 26.2

    Pattern-recognition receptors

    • PRRs are germline-encoded receptors that detect conserved microbial features and molecules released by damaged cells, so no clonal selection is needed.
    • Toll-like receptors sit on the surface or in endosomes: surface TLR4 senses bacterial LPS, while endosomal TLR3 senses viral double-stranded RNA and TLR9 senses unmethylated CpG DNA.
    • NOD-like and RIG-I-like receptors sit in the cytosol and sense intracellular bacteria and viral nucleic acid.
    • Signalling through NF-kB turns on inflammatory cytokines and interferons; some NLRs assemble inflammasomes that activate caspase-1 and release IL-1 beta.

    Outcome

    1. 9Compare pattern-recognition receptors (TLR, NLR, RLR) by location and ligand.
  10. 26.2

    Three complement pathways, one effector arm

    • Classical pathway is triggered when C1 binds antibody on antigen; lectin pathway when mannose-binding lectin binds microbial sugars; alternative when spontaneous C3 hydrolysis lands on a microbe.
    • All three produce C3 convertase, which cleaves C3 into C3a and C3b.
    • C3b opsonises; C3a and C5a bind mast cells to release histamine, and C5a attracts neutrophils.
    • C1 inhibitor deficiency causes hereditary angioedema; deficiency of terminal components predisposes to Neisseria infection.
    • C5b recruits C6, C7, C8 and several C9 into the membrane attack complex, which makes pores and lyses the microbe.

    Outcome

    1. 10Distinguish the classical, lectin and alternative complement pathways by trigger and shared effector steps.
  11. 26.2

    Innate effector cells

    • Neutrophils arrive first, squeeze out of vessels by chemotaxis and phagocytose; monocytes follow and mature into larger tissue macrophages.
    • Macrophages engulf microbes, dead neutrophils and debris, and secrete cytokines that recruit more cells.
    • NK cells kill virus-infected and tumour cells by releasing perforin and granzymes, and are boosted by interferons and IL-2.
    • Dendritic cells ingest antigen, migrate through lymphatics to nodes and present it to T cells, bridging innate and adaptive immunity.

    Outcome

    1. 11Describe the roles of neutrophils, macrophages, NK cells and dendritic cells in innate defence.
  12. 26.2

    Mediators behind the cardinal signs

    • Histamine and prostaglandins dilate arterioles (redness, heat) and raise capillary permeability, so fluid leaves and produces swelling.
    • Kinins such as bradykinin act on nerve endings for pain; prostaglandins intensify and prolong the effects of histamine and kinins.
    • IL-1 and related cytokines act on the hypothalamus to raise body temperature, and fever strengthens interferon effects.
    • Neutrophils stick to the endothelium, squeeze through (emigration) and follow chemotactic gradients, which adds to local swelling and heat.

    Outcome

    1. 12Explain how histamine, prostaglandins, bradykinin and cytokines produce the cardinal signs of inflammation.
  13. 26.3

    MHC class I versus class II

    • MHC I is on every nucleated body cell (not red cells); MHC II is on antigen-presenting cells: dendritic cells, macrophages and B cells.
    • MHC I shows peptides from inside the cell (usually 8-10 residues, closed groove) to CD8; MHC II shows peptides taken up from outside (usually 13-25 residues, open groove) to CD4.
    • Both are also called HLA; unique to each person (except identical twins), so they drive transplant rejection.
    • HLA associations exist: HLA-B27 with ankylosing spondylitis; cross-presentation lets dendritic cells load exogenous antigen on MHC I.
    • T cells ignore self peptide in MHC but respond to foreign peptide, so MHC lets T cells judge what is inside a cell.

    Outcome

    1. 13Compare MHC class I and class II molecules by structure, cell distribution and the T-cell co-receptor each engages.
  14. 26.3

    Endogenous versus exogenous processing

    • Endogenous (cytosolic) antigens, such as viral proteins, are cut into peptides, loaded onto MHC I in the endoplasmic reticulum and displayed on the surface.
    • Exogenous antigens are phagocytosed by an APC, digested in the phagosome or endosome and loaded onto MHC II that was made in the ER and packaged in vesicles.
    • The two routes dictate responder: MHC I with CD8 cytotoxic cells, MHC II with CD4 helper cells.
    • Most cells can run the endogenous pathway; only professional APCs run the exogenous one.

    Outcome

    1. 14Distinguish the endogenous (cytosolic) from the exogenous (endosomal) antigen-processing pathway.
  15. 26.3

    Helper and cytotoxic T cells

    • Activated CD4 T cells secrete IL-2 and other cytokines; IL-2 drives proliferation of helper cells, cytotoxic cells, B cells and NK cells.
    • Subsets: Th1 (activates macrophages, IFN-gamma), Th2 (helps B cells, IgE and eosinophil responses), Th17 (recruits neutrophils), Tfh (helps germinal-centre B cells), Treg (suppress).
    • CD8 cytotoxic T cells recognise antigen on MHC I and kill by perforin and granzymes, which trigger apoptosis.
    • HIV infects CD4 cells, so loss of helper cells weakens both cellular and antibody responses.

    Outcome

    1. 15Describe the roles of CD4 helper subsets (Th1, Th2, Th17, Treg, Tfh) and CD8 cytotoxic T cells.
  16. 26.3

    Two signals and anergy

    • Signal 1 is the TCR binding peptide-MHC with CD4 or CD8 helping hold the pair together.
    • Signal 2 is co-stimulation, for example B7 on the APC engaging CD28 on the T cell; without it the cell is not activated.
    • Recognition without co-stimulation produces anergy: a prolonged unresponsive state, so self-antigens met on non-APCs do not provoke attack.
    • Inhibitory receptors such as CTLA-4 and PD-1 damp responses, and checkpoint inhibitors block them to free T cells against tumours.

    Outcome

    1. 16Explain why TCR engagement needs co-stimulation (CD28 with B7) and what anergy means.
  17. 26.3

    V(D)J recombination and receptor diversity

    • Receptor genes are assembled in developing lymphocytes by cutting and joining a few hundred versions of several small gene segments (V, D, J).
    • RAG1 and RAG2 carry out the cut; TdT adds random nucleotides at the joins, adding junctional diversity.
    • Pairing of two different chains (heavy with light, alpha with beta) multiplies the combinations.
    • In theory V(D)J rearrangement yields more than 10^16 distinct receptors; Tortora counts at least 10^9 epitopes recognised, from a genome of only about 35,000 genes.

    Outcome

    1. 17Outline V(D)J recombination and how it generates receptor diversity.
  18. 26.3

    Clonal selection and expansion

    • Each lymphocyte carries a receptor of one specificity, made before antigen exposure.
    • Antigen selects only the few cells whose receptors fit; those proliferate into a clone, with co-stimulation and IL-2 as drivers.
    • The clone splits into short-lived effector cells and long-lived memory cells that last for decades.
    • Memory is the basis of the faster, larger second response and of vaccination.

    Outcome

    1. 18Explain clonal selection and clonal expansion of antigen-specific lymphocytes.
  19. 26.4

    B-cell activation: T-dependent and T-independent

    • A naive B cell binds antigen via its surface Ig, internalises it and shows peptide on MHC II to a Tfh cell; CD40 with CD40L and cytokines then drive activation.
    • Within a germinal centre, somatic hypermutation alters the V genes, and selection for tighter binding gives affinity maturation.
    • Class switching changes the heavy-chain constant region (IgM to IgG, IgA or IgE) while keeping antigen specificity.
    • T-independent antigens, such as repeating polysaccharides, cross-link surface Ig and yield mostly IgM with little memory.
    • X-linked agammaglobulinaemia (BTK defect) removes B cells; CD40L deficiency causes hyper-IgM syndrome because class switching fails.

    Outcome

    1. 19Describe B-cell activation by T-dependent and T-independent antigens, including class switching and somatic hypermutation.
  20. 26.4

    The five antibody classes

    • IgG is a monomer, about 75% of blood antibody (Tortora gives 80%), and the only class to cross the placenta.
    • IgM is a pentamer, the first class secreted, and a strong complement activator; monomeric IgM and IgD are the B-cell receptor on naive cells.
    • IgA is about 15% of blood antibody (Tortora gives 10-15%) but dominant in secretions (tears, saliva, milk, gut), as a dimer, and guards mucous membranes.
    • IgE is under 0.1% of blood antibody; it sits on mast cells and basophils, mediates allergy and defends against parasitic worms.

    Outcome

    1. 20Compare IgG, IgM, IgA, IgE and IgD by structure, location and function.
  21. 26.4

    Fab and Fc: what each end does

    • Each antibody has two identical Fab arms (variable regions of heavy and light chains) that bind antigen, and one Fc stem formed by the paired heavy chains.
    • Fab alone can neutralise: binding a toxin or virus blocks its attachment to host cells.
    • Fc engages Fc receptors on phagocytes (opsonisation) and on NK cells (cell-mediated killing of coated targets).
    • Fc also binds C1 to start the classical complement pathway, giving lysis and C3b opsonin deposition.

    Outcome

    1. 21Relate antibody Fab and Fc regions to neutralisation, opsonisation and complement activation.
  22. 26.4

    Germinal-centre outcomes: plasma cell versus memory B cell

    • Plasma cells are antibody factories with abundant rough ER; they secrete large amounts of antibody for days to weeks and then die.
    • Memory B cells are long-lived, resemble the original clone, circulate and stay dormant until the same antigen returns.
    • Because memory cells outnumber the original naive clone, a repeat exposure gives a faster, more potent response.
    • Selection in the germinal centre favours higher-affinity clones, so later responses carry class-switched, higher-affinity antibody.

    Outcome

    1. 22Contrast the plasma cell and memory B cell fates of germinal-centre selection.
  23. 26.5

    Primary and secondary responses compared

    • Primary: a lag of about 10 days with no detectable antibody, then IgM rises (peak near day 14) and IgG follows, with a modest titre that wanes within weeks.
    • Secondary: the lag shrinks to only a few days, then a higher, faster, mainly IgG response that lasts months.
    • Secondary antibody has higher affinity, from somatic hypermutation and selection of memory clones.
    • Vaccines exploit this, which is why immunisation uses boosters spaced weeks to months apart.

    Outcome

    1. 23Compare the kinetics, dominant isotype and affinity of the primary and secondary antibody responses.
  24. 26.5

    Four types of hypersensitivity

    • Type I: IgE bound to mast cells and basophils; allergen causes histamine and other mediator release within minutes (anaphylaxis, hay fever); epinephrine treats anaphylaxis.
    • Type II: antibody against cell or matrix antigen: hemolytic anaemia, Goodpasture syndrome, Graves disease; complement lysis as in incompatible transfusion.
    • Type III: IgG or IgM immune complexes lodge under vessel endothelium and activate complement (glomerulonephritis, serum sickness, lupus).
    • Type IV: T-cell mediated and delayed, usually developing over 48 to 72 hours (tuberculin test, poison ivy); no antibody is involved.

    Outcome

    1. 24Classify type I to IV hypersensitivity by mediator, timing and a clinical example.
  25. 26.5

    Central and peripheral tolerance

    • Central tolerance acts in the primary lymphoid organs: self-reactive T cells are deleted in the thymus, and self-reactive immature B cells are deleted or inactivated in the marrow.
    • Peripheral tolerance acts after cells leave: anergy (signal 1 without signal 2), suppression by Treg, and B cells receiving no T-cell help.
    • Tolerance is the basis of self-recognition; failure lets lymphocytes attack the body and produces autoimmune disease.
    • Failures: APECED (AIRE mutation, thymic negative selection defect), IPEX (FOXP3 mutation, no Treg), Graves disease and lupus.

    Outcome

    1. 25Distinguish central from peripheral tolerance and give a mechanism for each.
  26. 26.5

    Hyperacute, acute and chronic rejection

    • MHC (HLA) mismatch is the reason grafts are rejected, because the host sees donor MHC as foreign.
    • Hyperacute: preformed antibody against donor antigens (ABO or HLA) triggers complement and vascular thrombosis immediately after reperfusion.
    • Acute: host T cells attack the graft via donor MHC, mostly early (heart-graft incidence peaks near 1 month, levels off by 1 year); immunosuppression can reverse it.
    • Chronic: slow vascular fibrosis and graft loss over years; the converse problem, graft-versus-host disease, occurs when donor T cells attack the host.

    Outcome

    1. 26Compare hyperacute, acute and chronic transplant rejection.
  27. 26.5

    Primary versus acquired immunodeficiency

    • Primary immunodeficiencies are inherited gene defects: SCID affects both T and B arms and children die of opportunistic infection without treatment.
    • DiGeorge syndrome (thymic aplasia) leaves T cells low; complement deficiency is another primary defect.
    • Acquired immunodeficiencies arise from infection, drugs or disease; HIV is the model.
    • HIV uses CD4 as its receptor, so helper T cells decline until opportunistic disease appears.
    • AIDS is diagnosed at a helper T cell count below 200 cells per microliter, or earlier on an opportunistic infection.

    Outcome

    1. 27Differentiate primary immunodeficiencies from acquired ones.